Cidofovir: A new therapy for cytomegalovirus retinitis

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 14, Issue SUPPL. 1, 1997, Pages

  Lalezari, Jacob P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Cidofovir; CMV retinitis; Cytomegalovirus; Foscarnet; Ganciclovir; HPMPC; Probenecid

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; PROBENECID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL MODEL; ANTIVIRAL ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RAT; RETINITIS; SPECIES DIFFERENCE;

ANIMALIA; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 0030897796     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199700001-00005     Document Type: Conference Paper

References (25)

1. Culliton BJ. AIDS - a treatable disease at last. Nature Med 1996;2:253.
2. Mellors JW. Closing in on human immunodeficiency virus-1. Antiretroviral therapy back on track with HIV-1 protease inhibitors. Nature Med 1996;2:274-5.
3. Hoover DR, Saah AJ, Bacellar H, et al., for the Multicenter AIDS Cohort Study. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med 1993;329: 1922-6.
4. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE, and the Zidovudine Epidemiology Study Group. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992;166:1223-7.
5. Drew WL. AIDS Commentary, cytomegalovirus infection in patients with AIDS. Clin Infect Dis 1992;14:608-15.
6. Jacobson MA. Current management of cytomegalovirus disease in patients with AIDS. AIDS Res Hum Retroviruses 1994;10:917-23.
7. Drew WL, Ives D, Lalezari JP, et al., for the Syntex Cooperative Oral Ganciclovir Study Group. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995;333:615-20.
8. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996;334:1491-7.
9. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol 1994;112:1531-9.
10. The Chiron Ganciclovir Implant Study Group. A randomized controlled multicenter clinical trial of a sustained-release intraocular ganciclovir implant in AIDS patients with CMV retinitis [Abstract]. Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995;243:1215.
11. Kuppermann BD. Therapeutic options for resistant cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retroviral 1997;14(suppl 1):S13-20 (this issue).
12. Bronson JJ, Ghazzouli I, Hitchcock MJM, Webb RR II, Kern ER, Martin JC. Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. J Med Chem 1989;32:1457-63.
13. Aduma P, Connelly MC, Srinivas RV, Fridland A. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates. Mol Pharmacol 1995;47:816-22.
14. Biron KK, Stanat SC, Sorrell JB, et al. Metabolic activation of the nucleoside analog 9-{[2-hydroxy-1-(hydroxymethyl) ethoxy]methyl}guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci USA 1985;82:2473-7.
15. Biron KK, Fyfe JA, Stanat SC, et al. A human cytomegalovirus mutant resistant to the nucleoside analog 9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc Natl Acad Sci USA 1986;83:8769-73.
16. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992;358:162-4.
17. Cherrington JM, Smith IL, Jiles RE, Fuller MD, Chen MS, Spector SA. Ganciclovir resistant CMV: implications of UL97 and polymerase mutations in cross resistance to cidofovir [Abstract]. Antiviral Res 1996;30:A44.
18. Stanat SC, Reardon JE, Erice A, Jordan MC, Drew WL, Biron KK. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob Agents Chemother 1991;35:2191-7.
19. Ho H-T, Woods KL, Bronson JJ, De Boeck H, Martin JC, Hitchcock MJM. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol Pharmacol 1992;41:197-202.
20. Lalezari JP, Drew WL, Glutzer E, et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995;171:788-96.
21. Hitchcock MJM, Jaffe HS, Martin JC, Stagg RJ. Review - antiviral portrait series: cidofovir, a new agent with potent anti-herpesvirus activity. Antiviral Chem Chemother 1996; 7:115-27.
22. Hitchcock MJM, Lacy SA, Lindsey JR, Kern ER. The cyclic congener of cidofovir has reduced nephrotoxicity in three species [Abstract]. Antiviral Res 1995;26:A358.
23. Holy A, Votruba I, Merta A, et al. Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro. Antiviral Res 1990;13:295-312.
24. Martin JC, Hitchcock MJM. Phosphonomethylether compounds as antiviral agents. Transplant Proc 1991;23:156-8.
25. Polis MA, Spooner KM, Baird BF, et al. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother 1995;39:882-6.